Urinary iron excretion depends on the mode of administration of the oral iron chelator 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one in patients with homozygous β‐thalassemia

Clinical Pharmacology & Therapeutics

Volumn 55, Issue 1, 1994, Pages 70-75

  Fassos, Frank F ^a   Klein, Julia ^a   Fernandes, Deolinda ^a   Matsui, Doreen ^a   Olivieri, Nancy F ^a   Koren, Gideon ^a  

^a Hospital for Sick Children ^*

Author keywords

[No Author keywords available]

Indexed keywords

CHELATING AGENT; DEFERIPRONE; DEFEROXAMINE; DRUG METABOLITE; HEMOGLOBIN; IRON;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BETA THALASSEMIA; BLOOD TRANSFUSION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; HUMAN; IRON CHELATION; IRON TRANSPORT; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BETA-THALASSEMIA; DRUG ADMINISTRATION SCHEDULE; FERRITIN; HEMOGLOBINS; HUMAN; IRON; IRON CHELATING AGENTS; PYRIDONES; SUPPORT, NON-U.S. GOV'T;

EID: 0027955093     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.1994.12     Document Type: Article

References (0)